Last reviewed · How we verify
Oraxol
At a glance
| Generic name | Oraxol |
|---|---|
| Also known as | Paclitaxel and HM30181AK-US, HM30181 methanesulfonate monohydrate, Oral paclitaxel capsules, HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules, oral HM30181A + oral paclitaxel |
| Sponsor | Athenex, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- An Open-label, Crossover Study of the Effect of Food on the Pharmacokinetics of Paclitaxel Administered Orally as Oraxol (Phase 1)
- Phase 1 Study With Expansion Cohorts to Assess the Safety, Tolerability, and Activity of Oraxol (Paclitaxel + HM30181A) in Combination With Pembrolizumab in Subjects With Advanced Solid Malignancies (Phase 1)
- A Phase I-II Clinical Trial to Determine Recommended Dose and to Assess the Efficacy, Safety and Pharmacokinetic Profile of Oral Paclitaxel(Oraxol®) in Patients With Advanced/Metastatic or Recurrent G (Phase 1)
- A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel (Phase 1)
- An Extension Study to Provide Oraxol to Patients Who Completed KX-ORAX-007 (Phase 1)
- A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Activity of Oraxol in Subjects With Advanced Malignancies (Phase 1)
- A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients (Phase 1)
- A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oraxol CI brief — competitive landscape report
- Oraxol updates RSS · CI watch RSS
- Athenex, Inc. portfolio CI